27 November 2026

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400001,
Maharashtra, India.

Scrip Code: 540975

The National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai 400051,
Maharashtra, India.

Scrip Symbol: ASTERDM

Dear Sir/ Madam,

Sub: Intimation of subscription to 2,00,000 Optionally Convertible Redeemable Preference Shares ("OCRPS") by way of rights issue of Alfaone Medicals Private Limited, an associate company of Aster DM Quality Care Limited ("Company")

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

With reference to the captioned subject and pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Company has today, i.e. 27 November 2026, subscribed to 2,00,000 Optionally Convertible Redeemable Preference Shares ("OCRPS") of face value of Rs. 10/- each at an issue price of Rs. 700/- each (including a security premium of Rs. 690/- each), aggregating to Rs. 14,00,00,000/- (Rupees Fourteen Crore only), offered by way of a rights issue by Alfaone Medicals Private Limited ("AMPL"), an associate company of the Company.

The details as required under Regulation 30 of the SEBI Listing Regulations read with Para A of Part A of Schedule III thereto and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are given in "**Annexure I**".

The above information will also be hosted on the website of the Company i.e. www.asterqualitycare.com.

This is for your information and records.

Thanking you,

For **Aster DM Quality Care Limited**
(formerly Aster DM Healthcare Limited)

HEMISH PURUSHOTTAM
Digitally signed by HEMISH PURUSHOTTAM
Date: 2026.11.27 20:21:07 +05'30'

Hemish Purushottam
Company Secretary and Compliance Officer
M. No.: A24331

Annexure I

Disclosure under Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr. No	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.;	**Name**: Alfaone Medicals Private Limited ("**AMPL**") **Date of incorporation**: December 3, 2020 **Authorized Share Capital**: Rs. 6,42,23,690/- (Rupees Six Crores Forty-Two Lakhs Twenty-Three Thousand Six Hundred and Ninety Only) comprising 24,22,369 equity shares of face value of Rs. 10/- each and 40,00,000 Optionally Convertible Redeemable Preference Shares of face value of Rs. 10/- each. **Paid-up Share Capital**: Rs. 6,10,71,840/- (Rupees Six Crore Ten Lakh Seventy-One Thousand Eight Hundred and Forty Only) comprising 23,52,941 equity shares of face value of Rs.10/- each and 37,54,243 Optionally Convertible Redeemable Preference Shares ('OCRPS') of face value of Rs. 10/- each. **Turnover**: For the financial year ended 31 March 2026: Rs 5.90 crores
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	AMPL, being an associate company of the Company, is a related party of the Company and the transaction falls within the ambit of related party transactions. The transaction is on an arm's length basis supported by a valuation report issued by Santosh N & Co, practicing Chartered Accountants
3	Industry to which the entity being acquired belongs	Healthcare Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The investment by the Company is being made for general corporate purposes.

Sr. No	Particulars	Details
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition;	The proposed acquisition is expected to complete upon allotment of OCRPS and is expected to complete within 15 (fifteen) days of subscription date.
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
8	Cost of acquisition and/or the price at which the shares are acquired;	Rs.14,00,00,000/- (Rupees Fourteen Crore Only) OCRPS are acquired at Rs. 700/- each (Rupees Seven Hundred Only).
9	Percentage of shareholding / control acquired and / or number of shares acquired;	2,00,000 Optionally Convertible Redeemable Preference Shares of face value of Rs.10/- each acquired at Rs. 700/- each including security premium of Rs. 690/- each. **Pre-Acquisition:** Number and Percentage of Equity Shares: 11,50,941 (48.91%) Number and Percentage of OCRPS: 37,54,243 (100%) **Post-Acquisition:** Number and Percentage of Equity Shares: 11,50,941 (48.91%) Number and Percentage of OCRPS: 39,54,243 (100%)
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	AMPL has been incorporated on December 03, 2020, in Bengaluru, Karnataka, India, inter alia, to carry on the business of trading drugs and pharmaceuticals. **Year** / **Turnover (INR in Crores)** FY 2025 - 2026 / 5.90 FY 2024 - 2025 / 6.16 FY 2023 - 2024 / 6.22